References
- Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf 2013;22:1013–8.
- Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;19:408–17.
- Autret-Leca E, Deligne J, Leve J, et al. Drug exposure during the periconceptional period: a study of 1793 women. Paediatr Drugs 2011;13:317–24.
- Cole LA, Ladner DG, Byrn FW. The normal variabilities of the menstrual cycle. Fertil Steril 2009;91:522.
- Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med 1999;340:1796.
- Fournier T, Guibourdenche J, Evain-Brion D. Review: hCGs: different sources of production, different glycoforms and functions. Placenta 2015;36:S60–S5.
- Backström T, Haage D, Löfgren M, et al. Paradoxical effects of gaba-a modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 2011;191:46–54.
- Andreen L, Nyberg S, Turkmen S, et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009;34:1121–32.
- Deak T, Quinn M, Cidlowski JA, et al. Neuroimmune mechanisms of stress: sex differences, developmental plasticity and implications for pharmacotherapy of stress-related disease. Stress 2015;18:367–80.
- de Vries TPGM, Henning RH, Hogerzeil HV, Fresle DA. Guide to Good Prescribing, A practical Manual. World health organization, action programme on essential drugs, Geneva, Switzerland, 1994.